First Tracks Biotherapeutics (TRAX) entered into a securities purchase agreement for a private placement expected to raise approximately $200 million. The company agreed to sell 6,106,870 common shares at $32.75 per share to institutional investors. Expected gross proceeds exclude placement agent fees and other expenses.
Closing is expected on October 19, 2026, subject to customary closing conditions. First Tracks intends to use proceeds for general corporate purposes, including clinical development of ANB033, a CD122 antagonist. New and existing investors participated in the placement.
First Tracks Biotherapeutics (TRAX) reported statistically significant intestinal-damage and symptom benefits for ANB033 in its Phase 1b celiac disease gluten-challenge cohort.
Among 32 efficacy-evaluable patients, Week 6 changes in villus height-to-crypt depth ratio, a measure of intestinal damage, were -0.17 versus -0.66 on placebo, a +0.49 difference (p=0.009). Intestinal immune-cell density changed -1.20 versus +18.83, a -20.03 difference (p<0.001). The combined tissue score difference was +3.33 (p=0.002). ANB033 prevented symptom increases throughout the 14-day challenge; symptom-score differences were statistically significant on days 1–7. No ANB033 recipient had serious or severe adverse events or events causing treatment discontinuation; 88.9% reported an adverse event.
The company anticipates a late-stage celiac trial in 2027 and Cohort 2 top-line data in Q1 2027.
First Tracks Biotherapeutics (TRAX) will announce top-line celiac disease trial data and host an investor webcast on October 12, 2026. The data cover Cohort 1 of the global Phase 1b trial of investigational ANB033, a gluten-challenge study assessing prevention of mucosal damage. Results will appear in a morning press release and be reviewed at 8:30 a.m. ET/5:30 a.m. PT. A webcast replay will remain available for at least 30 days.
First Tracks Biotherapeutics (Nasdaq: TRAX) will participate in three investor conferences in September 2026: the Wells Fargo Healthcare Conference on September 9 (fireside chat and 1x1s), Citi's Biopharma Back to School Conference on September 10 (1x1s), and the Morgan Stanley Global Healthcare Conference on September 16 (1x1s). A live webcast and 30-day replay of the Wells Fargo fireside chat will be available on the company's investor website.
First Tracks Biotherapeutics (Nasdaq: TRAX) reported second quarter 2026 results and updated progress across its pipeline. Lead asset ANB033/b) received U.S. FDA Fast Track designation for celiac disease and completed enrollment of Cohort 1 in its Phase 1b gluten‑challenge trial, with top‑line data reaffirmed for Q4 2026 and Cohort 2 mucosal‑healing data expected in Q1 2027. A separate 50‑patient Phase 1b trial in eosinophilic esophagitis is enrolling, with top‑line data anticipated in Q3 2027. ANB101’s Phase 1a in healthy volunteers is complete, while strategic options are being evaluated for rosnilimab. Following its April 20, 2026 separation from AnaptysBio, the company reported in cash, cash equivalents and investments, Q2 2026 R&D expenses of $25.6 million, G&A expenses of $9.3 million, and a net loss of $33.4 million, or $0.95 per share, reiterating cash runway into Q2 2028.
First Tracks Biotherapeutics (Nasdaq: TRAX) will participate in two upcoming investor conferences. President and CEO Daniel Faga and other executives plan a presentation and one-on-one meetings at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, and one-on-one meetings at the Leerink Partners Therapeutics Forum on July 14, 2026.
A live webcast and 30-day replay of the Jefferies presentation will be available on the company’s investor relations website.
First Tracks Biotherapeutics (Nasdaq: TRAX) reported Q1 2026 results and a business update following its April 20 separation from AnaptysBio.
The company launched with $180 million in cash and equivalents, guiding to a roughly two-year cash runway focused on advancing ANB033 and strategic options for rosnilimab.
Q1 2026 R&D expenses were $34.0 million vs. $41.5 million in Q1 2025, while G&A expenses rose to $18.9 million from $9.8 million, largely tied to separation and stock-based compensation. Net loss was $50.5 million vs. $47.2 million a year earlier.
Phase 1b trials of ANB033 in celiac disease and eosinophilic esophagitis are ongoing, with top-line celiac data expected in Q4 2026 and eosinophilic esophagitis data in mid-2027. A completed End-of-Phase 2 FDA meeting clarified a potential registrational Phase 3 path for rosnilimab in rheumatoid arthritis, and First Tracks is evaluating strategic options for this asset. Phase 1a for ANB101 in healthy volunteers is nearing completion.
First Tracks Biotherapeutics (Nasdaq: TRAX) began trading on Nasdaq on April 20, 2026 after a spin-off from AnaptysBio. The company launched as a clinical-stage biotech with $180 million in cash and a stated two-year cash runway to advance antibody therapeutics for autoimmune and inflammatory diseases.
Its initial pipeline includes ANB033 (CD122 antagonist, Phase 1b for celiac disease and eosinophilic esophagitis), rosnilimab (pathogenic T cell depleter, completed Phase 2b for rheumatoid arthritis), and ANB101 (BDCA2 modulator, Phase 1a). Shares were distributed one-for-one to Anaptys shareholders as of April 6, 2026.